Boston Scientific cut its full-year outlook after two of its core heart-disease products faced unexpected challenges in the second quarter. Revenue from the Watchman heart implant, which is used to ...
Boston Scientific confirmed investors' worst fears Wednesday by cutting 2026 guidance for the second time this year. “This update today is not the outcome we planned or what you have come to expect ...
Boston Scientific cut its full-year outlook after two of its core heart-disease products faced unexpected challenges in the second quarter. Revenue from the Watchman heart implant, which is used to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results